RecruitingNCT07508319
Role of the Immune System in Preventing Laryngeal Cancer
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
Sponsor
European Institute of Oncology
Enrollment
3 participants
Start Date
Nov 19, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with head & neck cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07508319
Related Trials
SL-28 for Advanced Solid Tumours
NCT073417371 location
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT0767223611 locations
Improving Dental Care for Patients With Head and Neck Tumors
NCT073283471 location
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
NCT07459283
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
NCT076254231 location